Home Daily Stock Opinions and Ratings Sanofi-Aventis (SNY-N)

Trending stocks today

Northrop Grumman TC Energy Visa Inc. Martinrea Minto Apartment REIT Equinix, Inc. Cisco Check Point Software Tech SILVER BULL RESOURCES INC Block Inc Bed Bath & Beyond First Capital Realty First Industrial Realty Trust Dream Industrial REIT BETAPRO SP500 DAILY INVERSE ETF iShares 20+ Year Treasury Bond ETF BMO Covered Call Utilities ETF Bank of America Manulife Financial

Sanofi-Aventis (SNY-N)

88 watching

NYSE:SNY

54.42
0.45 (0.83%) 1d
Mar 31, 2023, 8:00 pm
0
WEAK BUY

Sanofi-Aventis(SNY-N)

26/07/2022
Sanofi-Aventis
Defensive and probably won't hurt you. Has low, steady growth with reasonable dividend growth. They are developing a Covid vaccine. It's as good as other drug companies, though slightly cheaper.
Pharma & Healthcare
Lorne Steinberg
$50.540
Unknown
UnlockRating
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Sanofi-Aventis(SNY-N)

16/06/2022
Sanofi-Aventis
(A Top Pick May 26/22, Down 12%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with SNY has triggered its stop at $49. To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 5.3%, when combined with previous buy recommendations.
Pharma & Healthcare
The Panic-Proof Portfolio (Stockchase Research)
$49.280
Unknown
UnlockRating
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Sanofi-Aventis(SNY-N)

26/05/2022
Sanofi-Aventis
Stockchase Research Editor: Michael O'Reilly With FDA approval to expand use of one of its key anti-inflammatory treatments, we again reiterate, SNY as a TOP PICK. The drug is expected to generate annual sales over $13 billion -- 30% more than previously estimated. The company is seeking further approval for use with COPD patients. It pays an annual dividend backed by a payout ratio under 45% of cash flow. We continue to recommend a stop loss at $49, looking towards an initial target of $71 -- potential 27% upside. Yield 3.14% (Analysts’ price target is $70.75)
Pharma & Healthcare
The Panic-Proof Portfolio (Stockchase Research)
$55.670
Unknown
UnlockRating
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Sanofi-Aventis(SNY-N)

29/03/2022
Sanofi-Aventis
Stockchase Research Editor: Michael O’Reilly We again reiterate, SNY (a top French biotech that produces a wide range of vaccines and pharmaceuticals by prescription), as a TOP PICK. It has announced a collaboration with a smaller developer that could be a game changer for its cancer related products. It recently beat recent analyst earnings expectations by 16% and is managing a 24% ROE. It pays an annual dividend backed by a payout ratio under 50% of cash flow. We recommend keeping the stop tight at $49, looking towards an initial target of $63 -- potential 22% upside. Yield 3.7% (Analysts’ price target is $63.00)
Pharma & Healthcare
The Panic-Proof Portfolio (Stockchase Research)
$51.410
Unknown
UnlockRating
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Sanofi-Aventis(SNY-N)

15/02/2022
Sanofi-Aventis
(A Top Pick Dec 28/21, Up 5.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with SNY is progressing well. We now recommend trailing up the stop (from $47) to $49.
Pharma & Healthcare
The Panic-Proof Portfolio (Stockchase Research)
$52.980
Unknown
UnlockRating
DON'T BUY

Sanofi-Aventis(SNY-N)

11/02/2022
Sanofi-Aventis
Pays good dividend and has solid balance sheet. Has been unable to produce Covid-19 vaccine. Wouldn't recommend buying.
Pharma & Healthcare
Darren Sissons
$52.770
No
UnlockRating
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Sanofi-Aventis(SNY-N)

29/12/2021
Sanofi-Aventis
Stockchase Research Editor: Michael O'Reilly SNY is a French biotech that produces a wide range of vaccines and pharmaceuticals by prescription and is reiterated as a TOP PICK. Its new management team has improved its internal drug pipeline and expanded margins and EPS since joining in 2018. It beat recent analyst earnings expectations by 16% and is managing a 25% ROE. It pays an annual dividend that should be announced in the next couple of months with a yield backed by a payout ratio under 50% of cash flow. We recommend trailing up the stop (from $45) to $47, looking towards an initial target of $64.50 -- 27% upside. Yield 3.85% (Analysts’ price target is $64.12)
Pharma & Healthcare
The Panic-Proof Portfolio (Stockchase Research)
$50.360
Unknown
UnlockRating
BUY

Sanofi-Aventis(SNY-N)

11/11/2021
Sanofi-Aventis
Given the size of the business, the debt is extremely manageable. Steady eddy dividend grower by mid-high single digits over time. Doesn't depend on one large drug, lots in the pipeline. When things get frothy, will underperform, but when things turn the other way it will do well. A pretty good bet.
Pharma & Healthcare
Lorne Steinberg
$51.450
Unknown
UnlockRating
WATCH

Sanofi-Aventis(SNY-N)

19/10/2021
Sanofi-Aventis
Trades around 15x PE and pays around a 4% dividend. Their future is in the vaccine side, but flu rather than Covid. Interesting company and worth studying further.
Pharma & Healthcare
Gordon Reid
$47.810
No
UnlockRating
PAST TOP PICK

Sanofi-Aventis(SNY-N)

31/08/2021
Sanofi-Aventis
(A Top Pick Mar 12/20, Up 36%) A world-class vaccine-maker. He likes pharmas going forward. SNY is facing a patent cliff, but have bought and are developing new drugs to solve this. He's happy to own and buy this.
Pharma & Healthcare
Norman Levine
$51.690
Owned
UnlockRating
DON'T BUY

Sanofi-Aventis(SNY-N)

10/06/2021
Sanofi-Aventis
Done well recently as part of the vaccine trade. No real revenue growth over the last 5 years. Stagnant profits. Decent dividend. See his Top Picks today for exposure to healthcare.
Pharma & Healthcare
John O'Connell, CFA
$53.870
No
UnlockRating
DON'T BUY

Sanofi-Aventis(SNY-N)

07/06/2021
Sanofi-Aventis
They are waiting for approval for their vaccine against COVID in Japan. They are pretty much an oncology firm. You have to compare against other companies in the sector. This one does fine with a PE of 8.8 times and the payout ratio is quite low. The dividends and cash flow are not growing, however. They have to come out with a blockbuster product. See his top picks today for a preferable.
Pharma & Healthcare
David Driscoll
N/A
Unknown
UnlockRating
BUY

Sanofi-Aventis(SNY-N)

17/05/2021
Sanofi-Aventis
A very good company. Pays a 3.5% dividend yield. Historically, he expected more from their Covid vaccine, though.
Pharma & Healthcare
Jim Cramer - Mad Money
$53.380
Unknown
UnlockRating
PAST TOP PICK

Sanofi-Aventis(SNY-N)

07/05/2021
Sanofi-Aventis

(A Top Pick Mar 12/20, Up 36%) The same idea as GSK. Hasn't done a whole lot. They are actually working on a Covid vaccine. In the meantime, non-covid visits have been decreased so there has been a hit on prescriptions. Once it comes back, they should do fine.

Pharma & Healthcare
Norman Levine
$51.780
Owned
UnlockRating
COMMENT

Sanofi-Aventis(SNY-N)

05/02/2021
Sanofi-Aventis
In late-2019, a new CEO arrive to turn things around by spinning off the so-so consumer business and making small acquisitions. However, Covid hit them hard, and their vaccine development has disappointed. Reported a solid quarter this morning with a slight revenue miss, but strong earnings beat and bullish guidance for 2021. The stock rose 2%. Will it get its groove back?
Pharma & Healthcare
Jim Cramer - Mad Money
$48.210
Unknown
UnlockRating
Showing 1 to 15 of 43 entries
Next PageNext Page

Sanofi-Aventis(SNY-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 2

Stockchase rating for Sanofi-Aventis is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Sanofi-Aventis(SNY-N) Frequently Asked Questions

What is Sanofi-Aventis stock symbol?

Sanofi-Aventis is a American stock, trading under the symbol SNY-N on the New York Stock Exchange (SNY). It is usually referred to as NYSE:SNY or SNY-N

Is Sanofi-Aventis a buy or a sell?

In the last year, 2 stock analysts published opinions about SNY-N. 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Sanofi-Aventis.

Is Sanofi-Aventis a good investment or a top pick?

Sanofi-Aventis was recommended as a Top Pick by on . Read the latest stock experts ratings for Sanofi-Aventis.

Why is Sanofi-Aventis stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Sanofi-Aventis worth watching?

2 stock analysts on Stockchase covered Sanofi-Aventis In the last year. It is a trending stock that is worth watching.

What is Sanofi-Aventis stock price?

On 2023-03-31, Sanofi-Aventis (SNY-N) stock closed at a price of $54.42.

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Get Access To Watchlist

Latest Buy Signals

ZTS-NZoetis Inc
Zoetis Inc
$166.44
2.29 (1.36%)
MSFT-QMicrosoft Corp
Microsoft Corp
$288.30
4.25 (1.45%)
CNQ-TCanadian Natural Rsrcs
Canadian Natural Rsrcs
$74.79
0.49 (0.65%)
DIS-NWalt Disney Co.
Walt Disney Co.
$100.13
2.03 (1.99%)
SU-TSuncor Energy Inc
Suncor Energy Inc
$41.96
0.02 (0.05%)
Advertising

Today's Top Picks

MFC-TManulife Financial
Manulife Financial
$24.80
0.23 (0.92%)
BAC-NBank of America
Bank of America
$28.60
0.30 (1.04%)
ZWU-TBMO Covered Call Utilities ETF
BMO Covered Call Utilities ETF
$11.35
-0.01 (-0.09%)
TLT-QiShares 20+ Year Treasury Bond ETF
iShares 20+ Year Treasury Bond ETF
$106.37
1.57 (1.45%)
HIU-TBETAPRO SP500 DAILY INVERSE ETF
BETAPRO SP500 DAILY INVERSE ETF
$14.41
-0.21 (-1.48%)

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

SCHW-NCharles Schwab Corp
Charles Schwab Corp
$52.38
-0.09 (-0.17%)
T-NAT&T
AT&T
$19.25
0.17 (0.88%)
FRC-NFirst Republic Bank
First Republic Bank
$13.99
0.30 (2.10%)
ORLY-QO'Reilly Automotive Inc
O'Reilly Automotive Inc
$848.98
7.48 (0.87%)
BKNG-QBooking Holdings Inc.
Booking Holdings Inc.
$2,652.41
42.65 (1.58%)

Most Recent Experts

Wong

Stan Wong

Private Wealth Management, ScotiaMcleod

Stockchase

Stockchase Insights

5i Research

Weiss

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Snipe

Jason Snipe, CIO, Odyssey Capital Advisors

Odyssey Capital Advisors

Lebenthal

Jim Lebenthal

Cerity Partners

Advertising
Advertising
logoTop pickslogoStockslogoRecentlogoWatchlist
© Stockchase Inc.